Search - tctmd.com

Displaying 1 - 20 of 53

Sort: Relevancy | Date

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

Aspirin Not Protective Against CVD in Black Patients

Caitlin E. Cox

December 18, 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Conference News AHA 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

Michael O'Riordan

November 14, 2019

News Daily News

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Michael O'Riordan

November 05, 2019

News Daily News

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

L.A. McKeown

October 23, 2019

News Daily News

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Michael O'Riordan

October 22, 2019

News Daily News

Statins Started in Kids With FH Provide Benefits in Adulthood

Yael L. Maxwell

October 17, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

Shelley Wood

October 01, 2019

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Shelley Wood

September 03, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Shelley Wood

August 31, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

Advertisement

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Aspirin Not Protective Against CVD in Black Patients

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Statins Started in Kids With FH Provide Benefits in Adulthood

Recurrent Events Common Among Young Patients With CAD

TCTMD’s Top 10 Most Popular Stories for September 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content